STOCKHOLM, May 20, 2026 /PRNewswire/ — Strong financial performance with commercial milestone reached
Events during the first quarter 2026
- Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment
- Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks
- The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China
- New long-term and real-world data for Leqembi, presented at the AD/PD™ conference in Copenhagen, showed that patients choose to remain on treatment over a long period and that the disease-slowing treatment effect was sustained for up to four years of treatment
- Sales of Leqembi exceeded EUR 500 M during Eisai’s financial year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 M
Events after the end of the period
- The Swedish NT Council announced that it currently does not recommend the introduction of Leqembi in Swedish healthcare
- The FDA has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi® Iqlik™ by three months. The application concerns subcutaneous administration of Leqembi as an initiation treatment for early Alzheimer’s disease. The new PDUFA date is August 24, 2026
- Eisai has provided a sales forecast for Leqembi of JPY 143.5 billion (approximately SEK 8.4 billion) for the company’s broken fiscal year 2026 (April 2026 to March 2027), corresponding to a growth of 63% compared with the previous year
Financial summary January – March 2026
- Net revenues amounted to SEK 437.6 M (1,289.6), of which SEK 160.8 M (96.0) related to royalty income for Leqembi and SEK 218.8 M (112.4) in a milestone payment from Eisai
- Operating profit amounted to SEK 210.8 M (1,075.3)
- Profit for the period amounted to SEK 212.4 M (1,021.5)
- Earnings per share before dilution amounted to SEK 2.40 (11.55)
- Earnings per share after dilution amounted to SEK 2.39 (11.53)
- Cash flow from operating activities amounted to SEK -166.0 M (11.8)
- Cash and cash equivalents, including short-term investments, amounted to SEK 2,034.6 M (788.6) at the end of the period
Comments from the CEO
“Each year of preserved function is of great significance for patients and their families”
The first quarter of 2026 was characterized by regulatory progress and strong financial performance, driven by increasing royalty income and a milestone linked to global sales of Leqembi.
Increased sales and milestone reached for Leqembi
Global sales of Leqembi continued to increase and reached JPY 26.2 billion during the quarter, generating SEK 161 million in royalty income (+68% compared with Q1 2025) and triggering a milestone payment of EUR 20 million as sales exceeded EUR 500 million during Eisai’s financial year 2025 (April 2025 – March 2026). The royalty income and milestone payment further strengthen our already very strong financial position. This also confirms that Leqembi addresses a significant medical need and that confidence in the underlying science remains strong. At the same time, it provides us with considerable financial flexibility to continue investing long term in our research and development portfolio. The positive …